Several clinical studies (9) suggest that serum biomarkers, notably Salivary glycan antigen (KL-6) and surfactant protein-D (SP-D), hold potential as tools for the early detection of T-DXd-induced ILD; however, their clinical applicability requires further validation in larger, prospective cohorts. This evidence concerns the gene MUC1 and interstitial lung disease.